Authors
Latest:
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Latest:
Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case ReportA case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Deepu Madduri, MD, on Research in Multiple Myeloma This Past YearThe expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Latest:
Liso-Cel Yields Long-Lasting Complete Responses in Heavily Pretreated MCLTreatment with liso-cel appears to result in clinically meaningful activity across several subgroups of patients with mantle cell lymphoma, including those with high-risk features.
Latest:
Pomalidomide Combo Shows Deep, Enduring Responses in R/R Multiple MyelomaData from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.
Latest:
Acalabrutinib Appears More Effective in Earlier Lines of Treatment for CLLA pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Latest:
THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung CancerTreatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.
Latest:
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate CancerMuhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
Latest:
Chemotherapy Combinations and the Phase 3 DUO-E TrialShannon N. Westin, MD, discusses chemotherapy options for endometrial cancer as well as the results of her phase 3 DUO-E trial.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney CancerA phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Latest:
Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative NeoplasmsCancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.
Latest:
Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast CancerIn an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.
Latest:
Retrospective Radiotherapy in IBD Data May Warrant Prospective ResearchRetrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Latest:
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICuMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
